Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper – Supportive and palliative care

3360 - 5-year adherence to adjuvant endocrine therapy among women with breast cancer: a nationwide study using group-based trajectory modeling.


28 Sep 2019


Proffered Paper – Supportive and palliative care


Victoria Memoli


Annals of Oncology (2019) 30 (suppl_5): v667-v670. 10.1093/annonc/mdz262


V. Memoli1, G. Lailler2, C. Le Bihan-Bejamin2, M.K. Bendiane3, S. Lauzier4, J. Mancini3, P. Bousquet2, A. Bouhnik5

Author affiliations

  • 1 Faculté De Medecine Spécialité Santé Publique, UMR 1252 SESSTIM AMU, INSERM, IRD, 13385 - Marseille/FR
  • 2 Survey, Monitoring And Assessment, French National Cancer Institute (INCa), Boulogne Billancourt/FR
  • 3 Medicine, UMR 1252 SESSTIM AMU, INSERM, IRD, 13385 - Marseille/FR
  • 4 Chu De Quebec, Population Health and Optimal Health Practices Research Unit, Quebec city/CA
  • 5 Medicine, SESSTIM-INSERMUMR912-IRD-AMU, 13006 Marsei - Marseille/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3360


Adjuvant endocrine therapy (AET) is an oral medication prescribed to women with hormone-sensitive breast cancer (BC). AET is recommended daily for at least 5 years to reduce recurrence and mortality risks. Studies showed that a high proportion of women do not take daily or do not persist with AET for the recommended duration. The objectives of this study were to identify: 1) AET adherence trajectories for the 5 years following AET initiation among women diagnosed with non-metastatic BC and 2) factors associated with these trajectories.


We used data from the French Cohorte Cancer which includes data on hospitalizations, ambulatory care and medication claims for all cancer cases diagnosed in metropolitan France (SNDS database) . Women diagnosed with a first non-metastatic BC in 2011 and who had ≥1 AET claim in the 12 months after surgery were included in this study. For each woman, we estimated the proportion of days covered (PDC) by an AET for each month in the 5 years after AET initiation. Monthly PDCs were used to model AET adherence trajectories using Group-based trajectory modeling (GBTM). Statistical criteria were used to select the number of trajectories and evaluate the adequacy of the selected model. Factors associated with trajectories were identified using multinomial logistic regressions comparing.


33 260 women were included. A 6-trajectory model wasselected: 1) 6.6% stopped the treatment by the end of the first year of treatment, 2) 5.7% declined adherence around half-term treatment 3) 6.3% after around 3 years, 4) and 8.3% after 4 years, 5) adherence varied between 50% and 60% without ever stopping for 4.3% of women and 6) 68.8% had an optimal adherence over the whole duration of treatment. Factors associated with trajectories included age, switch of molecule of AET during the treatment and the type of surgery.


To our knowledge, this is the first nationwide study to describe 5-year AET adherence trajectories. By identifying the timing of AET decline and/or cessation and factors associated with longitudinal adherence patterns, results could guide the development of interventions aimed at supporting women having an AET.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Institut National du Cancer (INCa).




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.